Why is Vogenx stock surging today?
© Pavlo Gonchar / SOPA Images/Sipa via Reuters Connect Investing.com -- Amylyx Pharmaceuticals stock surged approximately 24.9% in pre-open trading today as investors positioned ahead of a highly anticipated readout from the company’s Phase 3 LUCIDITY clinical trial of avexitide, a first-in-class GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia — a serious condition that can develop in patients following bariatric weight-loss surgery. The company confirmed it would release topline results this morning and host a senior management conference call at 8:00 a.m.
Reported by 3 outlets — Investing.com · Stock Market. See all sources ↓
© Pavlo Gonchar / SOPA Images/Sipa via Reuters Connect Investing.com -- Amylyx Pharmaceuticals stock surged approximately 24.9% in pre-open trading today as investors positioned ahead of a highly anticipated readout from the company’s Phase 3 LUCIDITY clinical trial of avexitide, a first-in-class GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia — a serious condition that can develop in patients following bariatric weight-loss surgery. The company confirmed it would release topline results this morning and host a senior management conference call at 8:00 a.m. ET to discuss the findings, with the announcement refining the company’s prior guidance of a broader third-quarter 2026 timeline for the data release. Adding further fuel to the rally, Mizuho raised its price target on AMLX to $30 from $24 while maintaining an Outperform rating, citing higher launch pricing assumptions for avexitide and designating the stock a top 2026 pick ahead of the Phase 3 readout.
Read the full report at Investing.com · Stock Market ↗
Why it matters
3 outlets are covering this world story — one to watch as reporting develops.
- What's the story?
- © Pavlo Gonchar / SOPA Images/Sipa via Reuters Connect Investing.com -- Amylyx Pharmaceuticals stock surged approximately 24.9% in pre-open trading today as investors positioned ahead of a highly anticipated readout from the company’s Phase 3 LUCIDITY clinical trial of avexitide, a first-in-class GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia — a serious condition that can develop in patients following bariatric weight-loss surgery. The company confirmed it would release topline results this morning and host a senior management conference call at 8:00 a.m.
- How widely is it covered?
- 3 outlets, average source rating 6.0/10.
- When was it last updated?
- 2m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Why is Amylyx Pharmaceuticals stock surging today?
Sources1TypeCoverageInvesting.com · Stock Market